カテゴリ： GlobalData, アメリカ, 企業調査

Fate Therapeutics Inc (FATE)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Fate Therapeutics Inc (FATE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9798
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：79
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Fate Therapeutics Inc (Fate Therapeutics) is a biopharmaceutical company that develops programmed cellular therapies for cancer and immune disorders. The company’s pipeline product candidates include cellular immunotherapy pipeline, immuno-oncology candidates, and immuno-regulatory candidates. Its immuno-oncology product candidates include adaptive NK, pluripotent cell-derived cancer immunotherapies, and engineered CAR and TCR T- cell immunotherapies. Its products are derived from pluripotent cells. Fate Therapeutics uses ex vivo cell programming approach to include cell-surface proteins, rapid and supra-physiologic activation or inhibition of therapeutically-relevant genes, and to regulate the therapeutic function. The company’s immuno-regulatory cellular therapies promote immune system homeostasis for patients undergoing hematopoietic cell transplantation and immune disorders. Fate Therapeutics is headquartered in San Diego, California, the US.

Fate Therapeutics Inc (FATE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fate Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Fate Therapeutics Raises USD8 Million in Venture Financing 12
Fate Therapeutics Raises US$20 Million In Venture financing 13
Fate Therapeutics Raises US$9.2 Million In Venture financing 14
Partnerships 15
Fate Therapeutics Enters into Agreement with ONO Pharma 15
Fate Therapeutics Enters into Partnership with University of California San Diego 16
Fate Therapeutics Expands Research Agreement with Regents of the University of Minnesota 17
Fate Therapeutics Enters into Research Agreement with Boston Children’s Hospital 18
Licensing Agreements 19
Fate Therapeutics Enters into License Agreement with Gladstone Institutes 19
Fate Therapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 20
Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 22
Fate Therapeutics Enters into Licensing Agreement with Board of Trustees of the Leland Stanford Junior University 24
Equity Offering 25
Fate Therapeutics Raises USD143.8 Million in Public Offering of Shares 25
Fate Therapeutics Raises USD46 Million in Public Offering of Shares 27
Fate Therapeutics to Raise Funds through Public Offering of Shares 29
Fate Therapeutics to Raise USD37.5 Million in Private Placement of Preferred Stock 30
Fate Therapeutics to Raise USD19.3 Million in Private Placement of Shares 32
Fate Therapeutics Plans to Raise up to USD12.4 Million in Public Offering of Shares 34
Fate Therapeutics Raises USD10.3 Million in Private Placement of Shares 35
Fate Therapeutics Raises USD34.5 Million in Public Offering of Shares 36
Fate Therapeutics Completes IPO For US$46 Million 38
Fate Therapeutics Inc – Key Competitors 39
Fate Therapeutics Inc – Key Employees 40
Fate Therapeutics Inc – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
Nov 01, 2018: Fate Therapeutics reports third quarter 2018 financial results and highlights operational progress 42
Aug 06, 2018: Fate therapeutics announces second quarter 2018 financial results and highlights operational progress 44
May 10, 2018: Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress 46
Mar 05, 2018: Fate Therapeutics Announces Fourth Quarter 2017 Financial Results 48
Nov 01, 2017: Fate Therapeutics Reports Third Quarter 2017 Financial Results 50
Aug 14, 2017: Fate Therapeutics Reports Second Quarter 2017 Financial Results 52
May 15, 2017: Fate Therapeutics Reports First Quarter 2017 Financial Results 54
Mar 16, 2017: Fate Therapeutics Reports Fourth Quarter 2016 Financial Results 56
Corporate Communications 58
Oct 04, 2018: Fate Therapeutics names Wen Bo Wang, Ph.D. as Senior Vice President, Technical Operations 58
Sep 14, 2017: Fate Therapeutics Appoints Jim Beitel as Senior Vice President, Corporate Development 59
Product News 60
12/11/2017: Fate Therapeutics Announces Successful Completion of Technology Transfer and Initiation of IND-Enabling Manufacture of FT500 60
12/09/2017: Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8aß+ T Cells from Clonal Engineered Master Pluripotent Cell Line for Off-the-Shelf T-cell Immunotherapy 61
05/10/2017: Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 in Advanced Solid Tumors 62
03/13/2017: Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 Natural Killer Cell Cancer Immunotherapy 63
02/23/2018: Fate Therapeutics Announces Receipt of CIRM Grant for Clinical Translation of FT516 Off-the-Shelf Engineered NK Cell Cancer Immunotherapy 64
Clinical Trials 65
Apr 16, 2018: Fate Therapeutics Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to be Featured at 2018 AACR Annual Meeting Press Program 65
Mar 29, 2018: Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer Summit 2018 66
Mar 19, 2018: Fate Therapeutics Announces Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune 67
Feb 20, 2018: Fate Therapeutics Announces First Subject Treated with FATE-NK100 in DIMENSION Study for Advanced Solid Tumors 68
Dec 11, 2017: Fate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune and Initiation of Phase 2 Stage 70
Dec 08, 2017: Fate Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Cancer 72
Nov 10, 2017: Fate Therapeutics Announces Initial Clinical Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 for Relapsed / Refractory Acute Myelogenous Leukemia at SITC 2017 Annual Meeting 73
Nov 01, 2017: Fate Therapeutics Will Present Clinical Data From PROTECT Study of ProTmune at 2017 ASH Annual Meeting 75
Sep 18, 2017: Fate Therapeutics Initiates Phase 2 PROTECT Study of ProTmune for Prevention of Acute Graft-versus-Host Disease 76
Aug 08, 2017: Fate Therapeutics Announces Publication of Preclinical Data in Cancer Research and FDA Clearance of Third IND for FATE-NK100 77
Jan 05, 2017: Fate Therapeutics Announces First Patient Treated in ProTmune PROTECT Clinical Trial for the Prevention of Graft-Versus-Host Disease 78
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79

List of Tables
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fate Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fate Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Fate Therapeutics Raises USD8 Million in Venture Financing 12
Fate Therapeutics Raises US$20 Million In Venture financing 13
Fate Therapeutics Raises US$9.2 Million In Venture financing 14
Fate Therapeutics Enters into Agreement with ONO Pharma 15
Fate Therapeutics Enters into Partnership with University of California San Diego 16
Fate Therapeutics Expands Research Agreement with Regents of the University of Minnesota 17
Fate Therapeutics Enters into Research Agreement with Boston Children's Hospital 18
Fate Therapeutics Enters into License Agreement with Gladstone Institutes 19
Fate Therapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 20
Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 22
Fate Therapeutics Enters into Licensing Agreement with Board of Trustees of the Leland Stanford Junior University 24
Fate Therapeutics Raises USD143.8 Million in Public Offering of Shares 25
Fate Therapeutics Raises USD46 Million in Public Offering of Shares 27
Fate Therapeutics to Raise Funds through Public Offering of Shares 29
Fate Therapeutics to Raise USD37.5 Million in Private Placement of Preferred Stock 30
Fate Therapeutics to Raise USD19.3 Million in Private Placement of Shares 32
Fate Therapeutics Plans to Raise up to USD12.4 Million in Public Offering of Shares 34
Fate Therapeutics Raises USD10.3 Million in Private Placement of Shares 35
Fate Therapeutics Raises USD34.5 Million in Public Offering of Shares 36
Fate Therapeutics Completes IPO For US$46 Million 38
Fate Therapeutics Inc, Key Competitors 39
Fate Therapeutics Inc, Key Employees 40
Fate Therapeutics Inc, Subsidiaries 41

List of Figures
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Fate Therapeutics Inc (FATE)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Intermountain Healthcare Inc：企業の戦略的SWOT分析
    Intermountain Healthcare Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Braeburn Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Braeburn Inc (Braeburn), formerly Braeburn Pharmaceuticals Inc (Braeburn), is a biopharmaceutical company that develops medicines for the treatment of opioid addiction. The company’s lead product candidate CAM2038 is a weekly and monthly subcutaneous injection depot formulation of buprenorph …
  • Cleveland BioLabs Inc (CBLI)-医療機器分野：企業M&A・提携分析
    Summary Cleveland BioLabs Inc (Cleveland) is a biopharmaceutical company that develops and commercializes drugs to treat cancer, orphan indications and protect healthy tissues from radiation and chemotherapy. The company’s product includes entolimod, a recombinant protein which acts as an agonist of …
  • Havells India Ltd (HAVELLS)：企業の財務・戦略的SWOT分析
    Havells India Ltd (HAVELLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Electricity Generating Authority of Thailand：企業の戦略・SWOT・財務情報
    Electricity Generating Authority of Thailand - Strategy, SWOT and Corporate Finance Report Summary Electricity Generating Authority of Thailand - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • Mitsui E&S Holdings Co., Ltd. (7003)：企業の財務・戦略的SWOT分析
    Mitsui E&S Holdings Co., Ltd. (7003) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Nedbank Group Ltd (NED)：企業の財務・戦略的SWOT分析
    Nedbank Group Ltd (NED) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Athenex Inc (ATNX)：製薬・医療：M&Aディール及び事業提携情報
    Summary Athenex Inc (Athenex), formerly Kinex Pharmaceuticals LLC, is a biopharmaceutical company focused on the discovery, development and commercialization novel medicines and cell therapies for the treatment of cancers. The company’s orascovery products candidates include oral formulations of pac …
  • The Netherlands Cancer Institute-製薬・医療分野：企業M&A・提携分析
    Summary The Netherlands Cancer Institute (NCI) is a research institute that offers cancer research and treatment services. The institute conducts research in the areas of cell biology, diagnostic oncology, medical oncology, molecular carcinogenesis, biochemistry, biological stress response, gene reg …
  • Mphasis Limited：企業の戦略・SWOT・財務情報
    Mphasis Limited - Strategy, SWOT and Corporate Finance Report Summary Mphasis Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Sealed Air Corporation：企業のM&A・事業提携・投資動向
    Sealed Air Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sealed Air Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • GlaxoSmithKline Plc (GSK)：企業の財務・戦略的SWOT分析
    GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Bioasis Technologies Inc (BTI)：製薬・医療：M&Aディール及び事業提携情報
    Summary Bioasis Technologies Inc (BTI) is a developer and commercialize of pharmaceutical products and diagnostic technologies for central nervous system diseases and disorders. The company’s transcend program describes the proprietary carrier, p97 to deliver therapeutics and imaging agents across t …
  • Lifeway Foods Inc：企業の戦略・SWOT・財務情報
    Lifeway Foods Inc - Strategy, SWOT and Corporate Finance Report Summary Lifeway Foods Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Golden Agri-Resources Ltd：戦略・SWOT・企業財務分析
    Golden Agri-Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Golden Agri-Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Abivax SA (ABVX)：企業の財務・戦略的SWOT分析
    Summary Abivax SA (Abivax) is a biotechnology company that develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious and viral diseases. The company’s pipeline products include ABX464, ABX544 and ABX196. Its ABX464 is an oral small molecule to induce f …
  • Bankinter Banca Privada：企業の戦略・SWOT・財務情報
    Bankinter Banca Privada - Strategy, SWOT and Corporate Finance Report Summary Bankinter Banca Privada - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • United Energy Group Ltd (467)：石油・ガス：M&Aディール及び事業提携情報
    Summary United Energy Group Ltd (UEG) is an independent upstream oil and gas company that offers exploration and production of oil and gas reserves. The company's activities include merger and acquisition of oil and natural gas assets, exploitation, development and production of crude oil and natura …
  • Pakistan Water and Power Development Authority：企業の戦略的SWOT分析
    Pakistan Water and Power Development Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitor …
  • Eureka Therapeutics Inc-製薬・医療分野：企業M&A・提携分析
    Summary Eureka Therapeutics Inc (Eureka Therapeutics) which focuses on the development of novel T cell immunotherapies for the treatment of solid tumors. Its pipeline encompasses drug candidates for various indications such as liver cancer, hematological cancer, lung cancer, head and cervical cancer …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆